vandetanib + omeprazole

vandetanib + omeprazole describes the co-administration of two drugs: vandetanib, a *small molecule tyrosine kinase inhibitor* approved for the treatment of medullary thyroid cancer, and omeprazole, a widely used *proton pump inhibitor* for gastric acid-related disorders. Vandetanib inhibits key signaling pathways involved in tumor angiogenesis and growth, specifically acting on vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases. Omeprazole reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase (proton pump) in gastric parietal cells. Pharmacokinetic studies indicate that concurrent administration of vandetanib and omeprazole does not result in clinically significant drug-drug interactions. Vandetanib exposure (AUC) remains unchanged when combined with omeprazole, and neither drug requires dose adjustment when co-administered. The combination is generally well tolerated, though standard pharmacovigilance, including ECG monitoring for QT prolongation (related to vandetanib), should be practiced. No synergistic therapeutic intent is implied; this is not an approved fixed-dose combination, but reflects concomitant use, often due to supportive care (e.g., acid suppression) during vandetanib therapy[1][2][3].

Other names

vandetanib + omeprazole